Physician profile
David A Wrone
NPI 1043276108
$415.11
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $13.00 · 2021: $40.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $128.79 | 2019 | |
| Lilly USA, LLC | $44.33 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $40.51 | 2019 | |
| Pfizer INC. | $30.00 | 2019 | |
| Mayne Pharma Commercial LLC | $29.72 | 2019 | |
| Genentech USA, INC. | $27.42 | 2019-2020 | |
| Almirall LLC | $26.04 | 2021 | |
| Galderma Laboratories, L.P. | $14.99 | 2019 | |
| Epi Health, LLC | $14.01 | 2019 | |
| Amgen INC. | $13.62 | 2019 | |
| Celgene Corporation | $12.30 | 2019 | |
| Janssen Biotech, INC. | $11.32 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.20 | 2019 | |
| Allergan, INC. | $10.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.